Christopher Horan, Chief Tech Operations Officer of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), filed a Form 4 on September 11, 2026, disclosing equity awards granted on September 9, 2026.

Key Highlights

  • RSU Award: Horan acquired 40,000 shares of Common Stock via a restricted stock unit award at a price of $0, granted under the issuer's 2024 Equity Incentive Plan.
  • Stock Option Grant: Horan received an employee stock option (right to buy) covering 120,000 shares of Common Stock at an exercise price of $10.79 per share.
  • Option Vesting: Beginning September 8, 2026, 1/48th of the option shares vest in equal monthly installments over a four-year period.
  • Option Expiration: The stock option expires on September 8, 2036.
  • Post-Transaction Ownership: Following the reported transactions, Horan directly holds 323,084 shares of Common Stock and 120,000 derivative securities.
  • Transaction Code: Both awards were coded "A" (acquired) with a derivative security price of $0.

Artiva Biotherapeutics CTOO Equity Awards: RSUs and Stock Options Detailed

According to the Form 4 filed with the SEC on September 11, 2026, Christopher Horan, identified as Chief Tech Operations Officer of Artiva Biotherapeutics, Inc., received two separate equity awards on September 9, 2026. The first is a restricted stock unit award for 40,000 shares of Common Stock acquired at a price of $0, granted under the issuer's 2024 Equity Incentive Plan. Following this acquisition, the filing reports Horan directly holds 323,084 shares of Common Stock in total.

The second award disclosed in the filing is an employee stock option granting the right to buy 120,000 shares of Common Stock at a conversion or exercise price of $10.79. The filing states that beginning on September 8, 2026, 1/48th of the shares subject to the option shall vest in equal monthly installments over a four-year period, with the option set to expire on September 8, 2036. The price of the derivative security is listed as $0, and Horan beneficially owns 120,000 derivative securities following the reported transaction, held directly.

The Form 4 was signed by Jennifer Bush as Attorney-in-Fact on September 11, 2026, and indicates this was filed by one reporting person. No amendment date is listed, and no indirect ownership is reported for either the common stock or derivative security positions disclosed in this filing.

What Was Disclosed

The filing discloses two equity grants to Artiva Biotherapeutics' Chief Tech Operations Officer: a 40,000-share RSU award at $0 under the 2024 Equity Incentive Plan, and a 120,000-share stock option at $10.79 per share expiring September 8, 2036, with monthly vesting over four years.